Stoke Therapeutics (STOK) Capital Expenditures (QoQ) (2018 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Capital Expenditures (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 459.77% |
| Mar 31, 2026 | 52.16% |
| Dec 31, 2025 | 75.76% |
| Sep 30, 2025 | -14.29% |
| Jun 30, 2025 | 1.32% |
| Mar 31, 2025 | 261.90% |
| Dec 31, 2024 | -59.22% |
| Sep 30, 2024 | 123.91% |
| Jun 30, 2024 | 283.33% |
| Mar 31, 2024 | -94.76% |
| Dec 31, 2023 | -40.21% |
| Sep 30, 2023 | -16.56% |
| Jun 30, 2023 | -15.78% |
| Mar 31, 2023 | 33.25% |
| Dec 31, 2022 | -79.85% |
| Sep 30, 2022 | 197.65% |
| Jun 30, 2022 | -18.91% |
| Mar 31, 2022 | 211.48% |
| Dec 31, 2021 | -1.10% |
| Sep 30, 2021 | -47.50% |